Doctors have successfully dropped the first "smart bomb" on breast cancer, using a drug to deliver a toxic payload to tumor cells while leaving healthy ones alone.
Doctors have successfully dropped the first "smart bomb" on breast cancer, using a drug to deliver a toxic payload to tumor cells while leaving healthy ones alone.
CHICAGO (Reuters) - Colorectal cancer patients treated with a follow-up round of Avastin fare better than those given chemotherapy alone after their disease has worsened, according to results of a large clinical trial. Avastin, sold by Roche, is approved as a first-line or second-line treatment for colorectal cancer, but not for both. Sales of the drug, also known as bevacizumab, totaled $5.3 billion Swiss francs ($5.5 billion) last year. ...
CHICAGO (Reuters) - A study of Roche's experimental "armed antibody" found it extended the length of time breast cancer patients lived without their disease getting worse, marking the second successful pivotal trial in this new class of cancer drugs. The drug, TDM-1, uses Roche's antibody drug Herceptin to deliver a potent cell-killing payload developed by ImmunoGen directly into cancer cells, with the aim of boosting drug response while lowering the risk of side effects. ...
By JESSICA YARBER, M.D. Can allergies increase your risk of cancer? A new study out of University of Washington Fred Hutchinson Cancer Research Center suggests this may be the case. Specifically, the study found that patients with allergies may have a higher risk of developing...